Current Edition

Hyaluronic Acid – Creation of Slow Release Formulations for Osteoarthritis Treatments

Osteoarthritis (OA) is the world’s most common degenerative joint disorder, affecting more than 60% of the population over the age of 65.During this condition, bone surfaces come into contact under ordinary loads, leading to severe pain and disability and leading to symptoms including subchondral bone sclerosis, progressive articular cartilage loss and synovial fluid viscosity decrease. Hans Ole at Novozymes Biopharma provides an overview into the HA, and the cost of the treatment.